1. Home
  2. NB vs ECOR Comparison

NB vs ECOR Comparison

Compare NB & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NB
  • ECOR
  • Stock Information
  • Founded
  • NB 1987
  • ECOR 2005
  • Country
  • NB United States
  • ECOR United States
  • Employees
  • NB N/A
  • ECOR N/A
  • Industry
  • NB Metal Mining
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • NB Basic Materials
  • ECOR Health Care
  • Exchange
  • NB Nasdaq
  • ECOR Nasdaq
  • Market Cap
  • NB 56.9M
  • ECOR 65.0M
  • IPO Year
  • NB N/A
  • ECOR 2018
  • Fundamental
  • Price
  • NB $1.38
  • ECOR $15.47
  • Analyst Decision
  • NB Strong Buy
  • ECOR Strong Buy
  • Analyst Count
  • NB 1
  • ECOR 1
  • Target Price
  • NB $8.50
  • ECOR $25.00
  • AVG Volume (30 Days)
  • NB 179.6K
  • ECOR 115.9K
  • Earning Date
  • NB 02-11-2025
  • ECOR 11-13-2024
  • Dividend Yield
  • NB N/A
  • ECOR N/A
  • EPS Growth
  • NB N/A
  • ECOR N/A
  • EPS
  • NB N/A
  • ECOR N/A
  • Revenue
  • NB N/A
  • ECOR $23,327,000.00
  • Revenue This Year
  • NB N/A
  • ECOR $61.40
  • Revenue Next Year
  • NB N/A
  • ECOR $38.43
  • P/E Ratio
  • NB N/A
  • ECOR N/A
  • Revenue Growth
  • NB N/A
  • ECOR 74.10
  • 52 Week Low
  • NB $1.27
  • ECOR $5.25
  • 52 Week High
  • NB $4.00
  • ECOR $17.84
  • Technical
  • Relative Strength Index (RSI)
  • NB 43.84
  • ECOR 67.43
  • Support Level
  • NB $1.36
  • ECOR $13.22
  • Resistance Level
  • NB $1.74
  • ECOR $14.87
  • Average True Range (ATR)
  • NB 0.13
  • ECOR 1.39
  • MACD
  • NB 0.00
  • ECOR 0.25
  • Stochastic Oscillator
  • NB 14.29
  • ECOR 67.21

About NB NioCorp Developments Ltd.

NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Share on Social Networks: